pd 153035 and bortezomib

pd 153035 has been researched along with bortezomib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
An, J; Rettig, MB	1

Other Studies

1 other study(ies) available for pd 153035 and bortezomib

Article	Year
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Molecular cancer therapeutics, 2007, Volume: 6, Issue:1 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Cycle; Cell Death; Cell Survival; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Inhibitory Concentration 50; Kidney Neoplasms; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines	2007

Article

Year

Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.

Molecular cancer therapeutics, 2007, Volume: 6, Issue:1

Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Cycle; Cell Death; Cell Survival; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Inhibitory Concentration 50; Kidney Neoplasms; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines

2007